Background: The multi-kinase inhibitor sorafenib displays antitumoral effects in head and neck squamous cell carcinoma (HNSCC); however, the targeted kinases are unknown. Here we aimed to identify those kinases to determine the mechanism of sorafenib-mediated effects and establish candidate biomarkers for patient stratification. Methods: The effects of sorafenib and MET inhibitors crizotinib and SU11274 were analyzed using a slide-based antibody array, Western blotting, proliferation, and survival assays. X-rays were used for irradiations. Results: Sorafenib inhibited auto-phosphorylation of epidermal growth factor receptor and MET, which has not been described previously. MET expression in HNSCC cells was not always associated with activity/phosphorylation. Furthermore, sorafenib-dependent cell kill and radiosensitization was not associated with MET level. Although MET inhibitors blocked proliferation, they caused only mild cytotoxicity and no radiosensitization. Conclusion: We identified MET as a new potential target of sorafenib. However, MET inhibition is not the cause for sorafenib-mediated cytotoxicity or radiosensitization.
| INTRODUCTION
Molecular targeting is expected to improve the treatment of head and neck squamous cell carcinoma (HNSCC), both in the palliative and the curative setting. Various strategies have been tested in clinical and preclinical studies, many of them using drugs directed against hyperactivated kinases. So far, these efforts have led to the approval of cetuximab in combination with either chemotherapy or irradiation. 1 Although many targeting strategies show very promising results initially, response is often limited to a subset of patients, arguing for predictive biomarkers and personalized treatment regimens.
In this context, we have demonstrated that the small molecule inhibitor sorafenib causes significant cell inactivation and growth retardation in HNSCC cells. 2, 3 Although not interacting with cisplatin-mediated cell inactivation, sorafenib enhances the efficacy of X-irradiation, leading to radiosensitization and a striking overall cell kill. 3 Sorafenibmediated radiosensitization of cancer cells is probably caused by compromised DNA repair 2, 4 and can be observed in various other entities such as colorectal, liver, or breast cancer. [5] [6] [7] [8] It is not, however, a general phenomenon because glioblastoma cells were not sensitized. 9 Additionally, although its effects on proliferation and cell inactivation without irradiation can be observed in every tested HNSCC cell line, radiosensitization can only be observed in selected cell lines, arguing for 2 groups of HNSCC, responding and nonresponding cell lines in terms of sorafenib-mediated radiosensitization. 2, 3 Because the use of sorafenib as a monotherapy did not achieve a convincing therapeutic effect in HNSCC, 10, 11 sorafenib may only be clinically useful as a radiosensitizer for responsive tumors. Unfortunately, no biomarkers are available to discriminate responders from nonresponders, preventing the efficient use of sorafenib in the context of radiotherapy/chemotherapy. Additionally it is still unclear which kinases are inhibited by sorafenib in HNSCC, because the activity of its main known targets like Raf kinases is not affected in HNSCC. 2 In this study, we therefore wanted to identify target kinases for sorafenib and determine their role in cellular effects like growth inhibition, cell inactivation, and radiosensitization of HNSCC cells. Because there is a special need to improve the therapy for human papilloma virus (HPV)-negative HNSCC due to the comparatively bad prognosis, 12 we focused only on HPV-negative HNSCC.
| MATERIALS AND METHODS

| Cell lines
HPV-negative HNSCC cells and normal fibroblasts (F180)
were grown in Dulbecco's Modified Eagle Medium (Invitrogen, Carlsbad, California) containing 10% fetal calf serum (PAN Biotech, Aidenbach, Germany) and 2 mM glutamine (Invitrogen) at 37 C and 100% humidification.
Squamous cell carcinoma (SCC) cell lines were kindly provided by Prof. Dr. Reidar Grénman from the University Hospital Turku (UT), Finland. Cells were identified by a short tandem repeat multiplex assay (Applied Biosystems, Foster City, California) if a reference was available.
| Substances
Sorafenib (Nexavar; Bayer HealthCare, Leverkusen, Germany), Crizotinib (LC Laboratories, Woburn, Massachusetts), and SU11274 (Abcam, Cambridge, United Kingdom) were dissolved in dimethyl sulfoxide (DMSO; Roche, Basel, Switzerland).
| Irradiation
Cells were irradiated at room temperature (RT) with 200 kV X-rays (Gulmay RS225; Gulmay Medical Ltd., Byfleet, United Kingdom; 15 mA, 0.8 mm Be +0.5 mm Cu filtering; dose rate of 1.2 Gy/min).
| Slide-based antibody array to analyze tyrosine kinase signaling
Proteins from whole-cell extracts were analyzed as specified by the manufacturer (Cell Signaling Technology, Danvers, Massachusetts). In brief, the antibody arrays were blocked and the cell lysates were incubated over night at 4 C under constant shaking. Unbound proteins were discarded and wells washed. After incubation with the detection antibody cocktail and subsequent washing, the wells were incubated with DyLight 680-linked Streptavidin. After another round of washing, the antibody array was rinsed with 10 mL purified water and completely dried. For fluorescence detection, the Odyssey CLx Infrared Imaging System (LI-COR, Lincoln, Nebraska) was used. Signals were quantified using either Image J or LI-COR Image Studio 2.1 software.
| Western blotting
Of note, 250 000 cells were seeded, and 24 hours later approximately 5 μg protein from whole-cell extracts were detected by Western blot according to standard protocols. After the transfer, the membranes were blocked using phosphate-buffered saline containing 0.2% Tween20 and 5% bovine serum albu- 
| Cell proliferation
To measure cell proliferation, 100000 cells were seeded, treated with inhibitors or DMSO as a control 24 hours later, and cell numbers were determined as indicated using a Coulter Counter (Beckmann, Indianapolis, Indiana).
| Colony formation assay
Cell survival was measured by colony formation under preplating conditions. Therefore, 250 cells were seeded in T25 flasks 24 hours before inhibitor treatment. After 2 hours of treatment, the cells were irradiated as indicated and the medium was changed 24 hours later, keeping the cells without inhibitor for the rest of the experiment. Because inhibitor treatment might affect proliferation, all samples were grown until colonies reached equal size. After 10-20 days, colonies were fixed and stained with crystal violet, and the colonies of more than 50 cells were scored as "survivors." The surviving fraction was either normalized to the plating efficiency of the non-irradiated DMSO sample or the nonirradiated samples of each treatment arm.
| Data evaluation
Unless otherwise indicated, experiments were repeated at least 3 times. The data are presented as mean values (SEM). Prism 5 software (GraphPad Software, La Jolla, California) was used for analyzing and graphing the data. To test for statistical significance, the unpaired student's t test was performed to calculate P-values (* P < .05; ** P < .01; *** P < .001).
3 | RESULTS
| Effect of sorafenib on HNSCC cells and cellular signaling
As reported previously, sorafenib inhibits cell proliferation ( Figure 1A ), induces significant cell inactivation ( Figure 1B ) and radiosensitizes HNSCC responder cells such as UT-SCC 42B 2,3 ( Figure 1C ) causing a massive overall cell inactivation (Supporting Information Figure S1A ). To identify the kinase(s), whose inhibition might be responsible for this radiosensitization, we first analyzed the effect of sorafenib on well-described targets such as Raf or PDGF receptor. 13 However, these kinases were either barely expressed or were not inhibited (see reference 2 and Supporting Information Figure S2 ). Because sorafenib is reported to predominantly block receptor tyrosine kinases (RTK), 13 we next analyzed the effect of sorafenib on RTK using an explorative slide-based antibody array that includes 38 RTK and RTK-dependent proteins ( Figure 2A ). Setting a threshold of 2-fold, the array identified at least 2 RTK which might be inhibited by sorafenib: the hepatocyte growth factor receptor (MET) and the epidermal growth factor receptor (EGFR). Using Western blot, we validated these results ( Figure 2B ). Because we detected autophosphorylation of tyrosine 1234/1235 (MET) and 1173
Effect of sorafenib on HNSCC cells. UT-SCC 42B cells were treated with dimethyl sulfoxide or 10 μM sorafenib. A, Proliferation was determined on the following days as indicated. B and C, Relative cell survival after 24 hours of sorafenib treatment as analyzed by colony formation assay without (B) or in combination with (C) X-irradiation. Cells were irradiated with 6 Gy after 2 hours of sorafenib treatment (* P < .05; ** P < .01; *** P < .001) Figure S1B ) were confirmed using SAS as a second responder line. 3 Although a reasonable block of HNSCC proliferation can be induced by EGFR inhibition, only minor cell inactivation and no efficient radiosensitization can be achieved as described recently. 14 Therefore, EGFR inhibition is probably not the cause for sorafenib-mediated cytotoxicity or radiosensitization, arguing for MET inhibition as the potential cause of sorafenib-mediated cellular effects. 
| MET expression and phosphorylation in HNSCC
Because MET seemed to be a promising target in HNSCC, we analyzed MET expression and phosphorylation in a panel of 32 HNSCC cell lines via Western blot ( Figure 4A ). SAS cells were used as a standard, whereas fibroblast cells (F180) were analyzed to compare expression to normal cells. As expected, most HNSCC cell lines displayed increased MET expression and phosphorylation compared to normal cells. Some HNSCC cells even showed very strong MET expression, like SAS and UT-SCC 19B, whereas others displayed moderate or only weak expression. Importantly, strong expression of MET was not always associated with increased MET phosphorylation, as detected for HSC4 and UT-SCC 16A cells, for example. But on average, MET phosphorylation correlated with expression as shown in Figure 4B . We observed no association between MET expression or phosphorylation and cellular radiosensitivity at 6 Gy (SF6; Supporting Information Figure S3A , B). With respect to sorafenib response, we observed high (SAS, UT-SCC 42B)
as well as low MET expression/phosphorylation levels (UT-SCC 29, UT-SCC 60A, and UT-SCC 60B) among responder (*) cell lines, indicating that inhibition of MET might not be the only parameter for sorafenib-mediated effects.
| Effect of MET inhibition on proliferation, cell survival, and cellular radiosensitivity
For further experiments, 2 already known responder cell lines with strong (SAS) and moderate MET phosphorylation (UT-SCC 42B) and 2 additional cell lines with strong (UT-SCC 14) and moderate expression (UT-SCC 19B) were chosen. Using the colony formation assay, both additional cell lines displayed remarkable cell kill after sorafenib treatment ( Figure 5A ) and turned out to be responder cell lines in respect of sorafenib-mediated radiosensitization ( Figure 5B ). Although radiosensitization was more pronounced in UT-SCC 14 cells, combined treatment resulted in an impressive overall cell inactivation for both cell lines (Supporting Information Figure S4A -B). To prove that sorafenib mediates its biological effects via MET inhibition, we also selected 2 small molecule inhibitors directed against MET, crizotinib and SU11274. Although crizotinib inhibits MET but also other tyrosine kinases like ALK and can be used to treat ALK-positive lung cancer, 15, 16 SU11274 is described to be highly specific for MET. 17 Crizotinib completely blocked MET phosphorylation at a concentration Cells were irradiated with 0, 2, 4, or 6 Gy after 2 hours of inhibitor treatment (* P < .05; ** P < .01; *** P < .001) of 0.05 μM, whereas 0.5 μM SU11274 was required to achieve a complete block ( Figure 6A ). For all 4 cell lines, an effective blockage of MET could be observed with both inhibitors ( Figure 6B ). Analyzing the effect of MET inhibition on proliferation, we observed no inhibitory effect of crizotinib in the submicromolar range and only mild effects for SU11274 ( Figure 7A ). Above 1 μM, more pronounced effects were apparent. Because we observed MET inhibition already at 50 nM (Crizotinib) and 0.5 μM (SU11274; Figure 6A ), offtarget blockage of other kinases is likely responsible for these antiproliferative effects. Without irradiation, MET inhibition only slightly affected cell survival in SAS and UT-SCC 14 cells but not in the other 2 cell lines as analyzed by colony formation assay ( Figure 7B) .
Next, we analyzed the effect of MET inhibition on cellular radiosensitivity. To this end, we incubated all 4 cell lines for 2 hours with MET inhibitors before irradiation. To avoid effects of proliferation inhibition on colony size, we changed the medium 24 hours after irradiation. Neither crizotinib nor SU11274 increased cellular radiosensitivity under the given conditions ( Figure 7C ), resulting only in moderate overall cell inactivation (Supporting Information Figure S5 ). This result demonstrates that the mechanism of sorafenib-mediated radiosensitization is independent of MET inhibition; hence, MET, although it is a target of sorafenib, is probably no target for cellular radiosensitization of HNSCC.
| DISCUSSION
Molecular targeting is a promising tool to improve the treatment of HNSCC, especially in combination with X-irradiation with the intent to radiosensitize the tumor cells. However, the underlying mechanisms have to be understood to enable precise and personalized treatment. In this context, we wanted to unveil the target(s) of multi-kinase inhibitor sorafenib, which inhibits proliferation and induces cell death and radiosensitization in a significant proportion of HNSCC cells. Using an explorative slide-based antibody array, we identified the RTK MET and EGFR as potential targets of sorafenib. With respect to EGFR, we have recently demonstrated that inhibition failed to induce significant cell death or robust radiosensitization in the cell lines used in this study. Although MET inhibition induces radiosensitization in other entities, [18] [19] [20] it also failed to do so in our HNSCC cells pretreated for 2 hours with 2 different MET inhibitors. Additionally, effects of crizotinib or SU11274 on proliferation and cell survival without irradiation turned out to be very limited in the sub-micromolar range, the concentration range where maximal MET inhibition was already achievable at the protein level (see Figure 6 ). This demonstrates that MET inhibition is likely not the cause of sorafenibinduced cell inactivation or radiosensitization. These results are in agreement with Baschnagel et al. 21 who also detected no radiosensitization and only moderate effects on cell survival in HNSCC using crizotinib. Nevertheless, the identification of EGFR and MET as new potential targets of sorafenib is very interesting, because both are important oncogenes in various cancer types 22, 23 and increased EGFR and MET expression are associated with worse prognosis in HNSCC. [24] [25] [26] Furthermore, sorafenib has also been described to interfere with tumor cell migration, invasion, and vascularization, 27 , which are also mechanisms that can be regulated by EGFR and MET. 23, 28 Therefore, EGFR and MET inhibition by sorafenib might still add to its antitumor activity, independently of the end points analyzed here. Although sorafenib has shown no clinical benefit in single treatment or in combination with cetuximab for advanced HNSCC, 10, 11, 29 its combination with radio-chemotherapy seems to be promising due to the observed cellular radiosensitization. Furthermore, it does not interfere with chemotherapy on the level of tumor cells but increases the survival of cisplatin-treated normal cells. 3 With respect to immunotherapies, sorafenib might lead to an immunosuppressive phenotype, which could be reverted by immune checkpoint inhibition as shown for liver cell cancer. 30, 31 However, both EGFR and MET have been also
shown to induce immune suppressive phenotypes, 32, 33 which might be attenuated by a treatment with sorafenib. To define optimal conditions for a possible use of sorafenib in HNSCC, such interactions have to be analyzed in detail using preclinical models in the future. The comparison of MET expression and phosphorylation in 32 HNSCC cell lines showed strong heterogeneity. We identified several cell lines with consistently weak expression and phosphorylation or strong expression and phosphorylation. However, we also identified cell lines with moderate MET expression showing moderate (eg, UT-SCC 15 and UT-SCC 24B), weak (eg, Cal33 and UT-SCC 42B), or even no (eg, SAT and UT-SCC 16A) detectable MET phosphorylation. These data emphasize the necessity to analyze phosphorylation or even the kinase activity rather than expression in the context of kinase-specific targeted therapeutics. Furthermore, we were not able to confirm any of the so-far described sorafenib targets such as Raf, PDGFR, VEGFR, or STAT in HNSCC (data not shown), arguing for different targets of sorafenib in the different cancer entities. With EGFR and MET, we have now identified 2 new potential targets of sorafenib in HNSCC which, however, seem not to confer cell inactivation nor radiosensitization but which are central molecules for targeted therapy in HNSCC.
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